Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

BACKGROUND: Verinurad is a human uric acid (UA) transporter (URAT1) inhibitor known to decrease serum UA (sUA) levels and that may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% con...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J L, Stack, Austin G, Terkeltaub, Robert, Greene, Tom A, Inker, Lesley A, Bjursell, Magnus, Perl, Shira, Rikte, Tord, Erlandsson, Fredrik, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317164/
https://www.ncbi.nlm.nih.gov/pubmed/34383954
http://dx.doi.org/10.1093/ndt/gfab237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317164/
https://www.ncbi.nlm.nih.gov/pubmed/34383954
http://dx.doi.org/10.1093/ndt/gfab237

Ejemplares similares